12,372 trials
Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Primary: Occurrence of Treatment-Emergent Adverse Events (AEs), AEs of Special Interest (AESIs), and Serious AEs (SAEs) by Injection Cycle, Overall and Related to the…
Acute Lymphoblastic Leukemia (ALL)
Primary: Number of Participants With Adverse Event to HD-MTX Treatment in NOPHO ALL-2008 as a Measure of Toxic Mtx Concentrations in Blood, Nephrotoxicity, Hepatotoxicity…
Nosocomial Pneumonia (NP) · Ventilator-associated Pneumonia (VAP)
Primary: The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set (Co-primary Analyses) — 245; 270; 79; 70…
Stage IIIB Lung Non-Small Cell Cancer AJCC v7 · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: Progression Free Survival (PFS) — 4.3; 2.6 months — p=0.0006
Multiple Sclerosis, Chronic Progressive
Primary: Brain Atrophy by MRI — -0.4; -1.3 whole brain percent volume change
Rheumatoid Arthritis
Primary: Brachial Artery Diameter Change From Baseline in Response to Reactive Hyperemia — 8.3; 9.43 % changes in diameter of artery
Postpartum Hemorrhage
Primary: Total Estimated Blood Loss — 512; 634 ml
Cystic Fibrosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 9; 24; 6; 5 participants
Anesthesia
Primary: Number of Participants Who Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic. — 88; 14 participants
Rheumatoid Arthritis
Primary: Percentage of Participants With Any Adverse Event (AE) — 93.3; 6.7; 93.3; 80.0 percentage of participants
Common Cold
Primary: Onset of Warming Sensation — 0.233 Minutes
Cardiac Arrest
Primary: Number of Participants Who Survive From the Time of Cardiac Arrest to Hospital Discharge — 237; 233; 222 participants
Cardiovascular Disease · Insulin Resistance · Glucose Intolerance
Primary: Change in Insulin Resistance From Baseline to 3 Months, as Measured by HOMA-IR — 3.57; 3.84; 3.81; 5.06 mg*microunits/dL*mL — p=0.34
Multiple Sclerosis
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 93.8; 91.3; 94.4; 91.2 percentage of participants
Urinary Bladder, Overactive
Primary: Change From Baseline to End of Treatment (EoT) in Mean Volume Voided (MVV) Per Micturition — 13.4; 25.5; 6.9; 2.3 mL — p=0.046